Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 5
1988 6
1989 5
1990 7
1991 9
1992 5
1993 7
1994 15
1995 10
1996 13
1997 13
1998 8
1999 15
2000 13
2001 11
2002 16
2003 19
2004 17
2005 17
2006 17
2007 14
2008 19
2009 14
2010 20
2011 31
2012 28
2013 25
2014 32
2015 29
2016 34
2017 38
2018 39
2019 38
2020 41
2021 56
2022 51
2023 55
2024 55
2025 58
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

833 results

Results by year

Filters applied: . Clear all
Page 1
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study.
Gabrielli G, Casadei B, Chiappella A, Tisi MC, Galli E, Cutini I, Di Rocco A, Donzelli L, Martino M, Policastro G, Crescimanno A, Petruzzellis G, Stella F, Visco C, Krampera M, Farina M, Angelillo P, Brunello L, Bruno B, Mannina D, Novo M, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL. Gabrielli G, et al. Among authors: zinzani pl. Blood Adv. 2026 May 5:bloodadvances.2025018749. doi: 10.1182/bloodadvances.2025018749. Online ahead of print. Blood Adv. 2026. PMID: 42085605
Pre-treatment circulating microRNA signatures predict outcomes of anti-CD19 CAR T-cell therapy.
Naddeo M, Roncarati R, De Felice F, Zuin E, Pace I, Iannotta F, Laprovitera N, Fontana B, Durante G, Salamon I, Storci G, De Matteis S, Ricci F, Bertuccio SN, Messelodi D, Ursi M, Roberto M, Barbato F, Ardizzoia F, Tomassini E, Sinigaglia B, Zazzeroni L, Dan E, Duardo RC, Vaglio F, Tassoni M, Pellegrini C, Gentilini M, Maffini E, Casadei B, Sales G, Zinzani PL, Bonafé M, Ferracin M, Bonifazi F. Naddeo M, et al. Among authors: zinzani pl. Haematologica. 2026 Apr 23. doi: 10.3324/haematol.2025.300294. Online ahead of print. Haematologica. 2026. PMID: 42021695 Free article.
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Mehta-Shah N, Zinzani PL, Jacobsen ED, Zain J, Mead M, Casulo C, Gritti G, Pinter-Brown L, Izutsu K, Sidransky D, Bentur OS, Pro B, Fox CP, Brammer JE, Horwitz SM. Mehta-Shah N, et al. Among authors: zinzani pl. J Clin Oncol. 2026 Apr 22:101200JCO2503120. doi: 10.1200/JCO-25-03120. Online ahead of print. J Clin Oncol. 2026. PMID: 42018969
Modern and multidisciplinary care in polycythemia vera.
Palandri F, Sartor C, Pileri A, Addimanda O, Gagliardi C, Sartori M, Benni M, Giannella M, Dato FL, Sabattini E, Fiorino L, Dedola A, Branzanti F, Rondinelli MB, Reta M, Galiè N, Viale P, Cosmi B, Placa M, Morelli MC, Zinzani PL. Palandri F, et al. Among authors: zinzani pl. Ann Hematol. 2026 Apr 18;105(5):251. doi: 10.1007/s00277-026-06970-w. Ann Hematol. 2026. PMID: 41999414 Free PMC article. Review.
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
Leonard JP, Trněný M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, Thieblemont C, Zinzani PL, Gkasiamis A, Ahn JR, Gribben JG; AUGMENT Trial Investigators. Leonard JP, et al. Among authors: zinzani pl. J Clin Oncol. 2026 Apr 16:JCO2501770. doi: 10.1200/JCO-25-01770. Online ahead of print. J Clin Oncol. 2026. PMID: 41990300
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R MD PhD, Li Y, Rule S, Furman RR. Owen RG, et al. Among authors: zinzani pl. Blood Adv. 2026 Apr 15:bloodadvances.2025017713. doi: 10.1182/bloodadvances.2025017713. Online ahead of print. Blood Adv. 2026. PMID: 41985004
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
Zent CS, Tiacci E, Kreitman RJ, Tadmor T, Tallman MS, Wörmann BJ, Andritsos LA, Arons E, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call TG, Dearden C, Demeter J, Dietrich S, El-Sharkawi D, Fagarasanu A, Falini B, Forconi F, Gerrie AS, Gladstone DE, Gozzetti A, Hampel PJ, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kipps TJ, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Rai KR, Ravandi F, Robak T Prof, Rogers KA, Saven A, Seymour JF, Tam CS, Troussard X, Zenz T, Zinzani PL, Grever MR. Zent CS, et al. Among authors: zinzani pl. Blood. 2026 Apr 14:blood.2025032757. doi: 10.1182/blood.2025032757. Online ahead of print. Blood. 2026. PMID: 41980020
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma.
Gugliotta G, Argnani L, Cantelli M, Pinto A, Gorgone A, Piazza F, Fozza C, Fesce VF, Marino F, Celli M, Pennese E, Gaudio F, Lauzzana P, Pezzullo L, Lorenzo S, Nierychlewska PM, Ceparano G, Pane F, Casadei B, Pellegrini C, Romano C, Zinzani PL. Gugliotta G, et al. Among authors: zinzani pl. Am J Hematol. 2026 Apr 10. doi: 10.1002/ajh.70317. Online ahead of print. Am J Hematol. 2026. PMID: 41960655
Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.
Trotman J, Bouabdallah K, Bijou F, Šálek D, de Oliveira AC, Song Y, Kingsley EC, Flowers CR, Liao S, Huang S, Shah N, Dumartin L, Zinzani PL. Trotman J, et al. Among authors: zinzani pl. ESMO Open. 2026 Apr;11(4):106942. doi: 10.1016/j.esmoop.2026.106942. Epub 2026 Mar 31. ESMO Open. 2026. PMID: 41922143 Free PMC article. Clinical Trial.
Small and Large Extracellular Vesicles in Circulation of Diffuse Large B-Cell Lymphoma Patients Originate From Different Cell Types of the Tumor Microenvironment.
Maltoni F, Wang S, Steketee MFB, Gómez-Martín CA, Drees EEE, Morelli F, Bosch L, van Eijndhoven M, Timmers GJ, Houtenbos I, Zijlstra JM, Ye X, Pan-Hammarström Q, Chamuleau MED, Zinzani PL, Kim Y, Catani L, Pegtel DM. Maltoni F, et al. Among authors: zinzani pl. J Extracell Vesicles. 2026 Apr;15(4):e70259. doi: 10.1002/jev2.70259. J Extracell Vesicles. 2026. PMID: 41885389 Free PMC article.
833 results